August 29th 2024
Experts discuss key takeaways and closing thoughts on antibody-drug conjugates (ADCs) in cancer treatment.
August 22nd 2024
Key opinion leaders examine promising antibody-drug conjugates (ADCs) in the pharmaceutical development pipeline.
Expert clinicians offer strategic guidance on optimal sequencing of antibody-drug conjugates (ADCs) in treatment protocols.
August 15th 2024
Experts provide clinical insights on the management of emetogenicity in patients receiving antibody-drug conjugates.
A panel of experts discuss hematologic adverse events associated with antibody-drug conjugate therapies.
February 10th 2019
Although there have been numerous studies evaluating the role of different therapy schedules, cytotoxic agents, and routes of administration in ovarian cancer, the backbone of therapy remains a combination of a platinum and a taxane.